By Sinchan Shah, Jaimin Shah and Stephen Auten ( February 12, 2019, 3:11 PM EST) -- Exorbitantly high prices are not just a problem for patented drugs. Even off-patent drugs are subject to high prices when there is inadequate generic competition due to market size or regulatory barriers. For example, the toxoplasmosis drug Daraprim, which has a small market (approximately, $10 million in 2015-16). Turing Pharmaceuticals acquired the product and immediately raised the price from $13.50 to $750 a pill.[1] The tuberculosis drug cycloserine is another example, where the price for 30 pills was raised from $500 to $10,800.[2]...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.